Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Protecting Our Communities from Gang Violence Act of 2018
Client: SANOFI US SERVICES INC · Firm: FOLEY HOAG LLP
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2024 · third_quarter · 3T
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
-Regulation of molecular diagnostics -Issues relating to Cures 2.0 Bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
| MYRIAD GENETIC LABORATORIES INC |
| 19 |
| 2011–2018 |
| NATIONAL VENTURE CAPITAL ASSOCIATION | 19 | 2007–2015 |
| EDITAS MEDICINES, INC. | 17 | 2016–2020 |
| SHIRE | 16 | 2015–2018 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 13 | 2001–2009 |
| TETHYS BIOSCIENCE | 13 | 2007–2010 |
| CELL THERAPEUTICS INC | 12 | 2003–2008 |
| CUBIST PHARMACEUTICALS | 12 | 2006–2009 |
| SCHOLASTIC | 12 | 2001–2008 |
| CAPELLA UNIVERSITY | 11 | 2001–2006 |
| SPECTRUM PHARMACEUTICALS | 10 | 2011–2016 |
| NOVARTIS | 9 | 2003–2008 |
| MYRIAD GENETICS INC | 8 | 2018–2019 |
| ACADEMY OF MOLECULAR IMAGING | 7 | 2000–2006 |
| EMPI | 6 | 2002–2006 |
| MA ASSN OF 766 APPROVED PRIVATE SCHOOLS | 6 | 2001–2003 |
| INVERNESS MEDICAL INNOVATIONS | 5 | 2009 |
| ANTIGENICS | 4 | 2001–2002 |
| BIOGEN | 4 | 2001–2003 |
| BIOGEN IDEC INC. | 4 | 2004–2006 |
| CALYPSO MEDICAL TECHNOLOGIES, INC. | 4 | 2007 |
| CAMBRIDGE HEART, INC. | 4 | 2004–2005 |
| CHIRON CORP | 4 | 2003–2004 |
| INTL ONCOLOGY NETWORK | 4 | 2004–2005 |
| NETWORK APPLIANCE | 4 | 2001–2002 |
| NEWSELA | 4 | 2015 |
| NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 4 | 2006–2007 |
| QLT | 4 | 2003–2005 |
| REDBRICK HEALTH | 4 | 2009 |
| BLOOM HEALTH | 3 | 2011 |
| DENOVIS | 3 | 2001–2002 |
| ELI LILLY AND COMPANY | 3 | 2008 |
| GUILFORD PHARMACEUTICALS | 3 | 2003–2004 |
| MERCK | 3 | 2003–2004 |
| PHOTOTHERA | 3 | 2007–2008 |
| ZOLL MEDICAL LIFEVEST | 3 | 2011 |
| ARDAIS | 2 | 2001–2002 |
| ASTRAZENECA PHARMACEUTICALS LP | 2 | 2005 |
| CATAPULT LEARNING | 2 | 2004 |
| CLEAN HARBORS | 2 | 2001–2002 |
| MCKESSON CORPORATION | 2 | 2014 |
| MEDICIS | 2 | 2007 |
| NEW ENGLAND NEUROLOGICAL ASSOC | 2 | 2006 |
| NEWBURY COLLEGE | 2 | 2003 |
| BLUEBIRD BIO | 1 | 2016 |
| CARDIODYNAMICS | 1 | 2006 |
| IDEC PHARMACEUTICALS CORP | 1 | 2003 |
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
Protecting Our Communities from Gang Violence Act of 2018
Client: SANOFI US SERVICES INC · Firm: FOLEY HOAG LLP
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Protecting Our Communities from Gang Violence Act of 2018
Client: SANOFI US SERVICES INC · Firm: FOLEY HOAG LLP
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Protecting Our Communities from Gang Violence Act of 2018
Client: SANOFI US SERVICES INC · Firm: FOLEY HOAG LLP
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Protecting Our Communities from Gang Violence Act of 2018
Client: SANOFI US SERVICES INC · Firm: FOLEY HOAG LLP
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Protecting Our Communities from Gang Violence Act of 2018
Client: SANOFI US SERVICES INC · Firm: FOLEY HOAG LLP
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Protecting Medicare from Executive Action Act of 2017
Client: SANOFI US SERVICES INC · Firm: FOLEY HOAG LLP
-Medicare Part B and D payment for drugs -Issues relating to IPAB in S. 251 "Protecting Medicare from Executive Action of 2017" -Issues related to the repeal of the non-interference clause in Part D
Protecting Medicare from Executive Action Act of 2017
Client: SANOFI US SERVICES INC · Firm: FOLEY HOAG LLP
-Medicare Part B and D payment for drugs -Issues relating to IPAB in S. 251 "Protecting Medicare from Executive Action of 2017" -Issues related to the repeal of the non-interference clause in Part D
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148). -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152). -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development. -Implementation of H.R. 6 - 21st Century Cures (P.L. 114-255). -S.2013 Trickett Wendler Right to Try Act of 2017. -H.R. 2430 and S. 932, FDA Reauthorization Act. -Issues related to Zika vaccine development. -Issues related to over-the-counter drug and cosmetic reform legislation.
Biological Implant Tracking and Veteran Safety Act of 2017
Client: BAXTER · Firm: FOLEY HOAG LLP
-End stage renal disease payment for home dialysis. -340B Drug Pricing Program. -Implementation of 21st Century Cures Legislation: Sec. 4013 - Telehealth Services in Medicare. -Implementation of 21st Century Cures Legislation: Sec. 17006 - Allowing ESRD Beneficiaries to Choose A Medicare Advantage Plan. -CONNECT for Health Act of 2017 - Discussion Draft. - H.R. 28: Biological Implant Tracking and Veteran Safety Act of 2017.
Biological Implant Tracking and Veteran Safety Act of 2017
Client: BAXTER · Firm: FOLEY HOAG LLP
-End stage renal disease payment for home dialysis. -340B Drug Pricing Program. -21st Century Cures Legislation: Sec. 4013 - Telehealth Services in Medicare. -21st Century Cures Legislation: Sec. 17006 - Allowing ESRD Beneficiaries to Choose A Medicare Advantage Plan. -CONNECT for Health Act of 2017 - Discussion Draft - H.R. 28: Biological Implant Tracking and Veteran Safety Act of 2017
Medicare Part B Home Infusion Services Temporary Transitional Payment Act
Client: SHIRE · Firm: FOLEY HOAG LLP
-Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics. -H.R. 6 - 21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy. -H.R. 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act -H.R. 3178 - Medicare Part B Improvement Act of 2017
Medicare Part B Home Infusion Services Temporary Transitional Payment Act
Client: SHIRE · Firm: FOLEY HOAG LLP
-Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics. -H.R. 6 - 21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy. -H.R. 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act -H.R. 3178 - Medicare Part B Improvement Act of 2017
Medicare Part B Home Infusion Services Temporary Transitional Payment Act
Client: SHIRE · Firm: FOLEY HOAG LLP
-Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics. -21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy. -H.R. 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act -H.R. 3178 - Medicare Part B Improvement Act of 2017
Medicare Part B Home Infusion Services Temporary Transitional Payment Act
Client: SHIRE · Firm: FOLEY HOAG LLP
-Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics. -21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy. -H.R. 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act -H.R. 3178 - Medicare Part B Improvement Act of 2017
-Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics. -H.R. 6 - 21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy. -H.R. 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act -H.R. 3178 - Medicare Part B Improvement Act of 2017
-Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics. -21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy. -H.R. 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act -H.R. 3178 - Medicare Part B Improvement Act of 2017
-Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics. -H.R. 6 - 21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy. -H.R. 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act -H.R. 3178 - Medicare Part B Improvement Act of 2017
-Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics. -21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy. -H.R. 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act -H.R. 3178 - Medicare Part B Improvement Act of 2017
Portfolio Lending and Mortgage Access Act
Client: SANOFI US SERVICES INC · Firm: FOLEY HOAG LLP
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148). -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152). -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development. -Implementation of H.R. 6 - 21st Century Cures (P.L. 114-255). -S.2013 Trickett Wendler Right to Try Act of 2017. -H.R. 2430 and S. 932, FDA Reauthorization Act. -Issues related to Zika vaccine development. -Issues related to over-the-counter drug and cosmetic reform legislation.
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: BAXTER · Firm: FOLEY HOAG LLP
-End stage renal disease payment for home dialysis. -340B Drug Pricing Program. -Implementation of 21st Century Cures Legislation: Sec. 4013 - Telehealth Services in Medicare. -Implementation of 21st Century Cures Legislation: Sec. 17006 - Allowing ESRD Beneficiaries to Choose A Medicare Advantage Plan. -S. 870: Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: BAXTER · Firm: FOLEY HOAG LLP
-End-stage renal disease payment for home dialysis. -Implementation of 21st Century Cures Legislation: Sec. 4013 - Telehealth Services in Medicare. -Implementation of 21st Century Cures Legislation: Sec. 17006 - Allowing ESRD Beneficiaries to Choose A Medicare Advantage Plan. -S. 870: Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148). -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152). -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development. -Implementation of H.R. 6 - 21st Century Cures (P.L. 114-255). -S.2013 Trickett Wendler Right to Try Act of 2017. -H.R. 2430 and S. 932, FDA Reauthorization Act. -Issues related to Zika vaccine development. -Issues related to over-the-counter drug and cosmetic reform legislation.
-Regulation of molecular diagnostics. -H.R. 6 - 21st Century Cures (P.L. 114-255).
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148). -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152). -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development. -Implementation of H.R. 6 - 21st Century Cures (P.L. 114-255). -S.2013 Trickett Wendler Right to Try Act of 2017. -H.R. 2430 and S. 932, FDA Reauthorization Act. -Issues related to Zika vaccine development. -Issues related to over-the-counter drug and cosmetic reform legislation.
-Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics. -H.R. 6 - 21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy.
-Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics. -H.R. 6 - 21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy. -H.R. 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act -H.R. 3178 - Medicare Part B Improvement Act of 2017
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148). -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152). -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development. -H.R. 6 - 21st Century Cures (P.L. 114-255).
-Regulation of molecular diagnostics. -H.R. 6 - 21st Century Cures (P.L. 114-255).
-Regulation of molecular diagnostics. -H.R. 6 - 21st Century Cures (P.L. 114-255).
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148). -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152). -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development. -H.R. 6 - 21st Century Cures (P.L. 114-255).
-Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics. -H.R. 6 - 21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy. -H.R. 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act -H.R. 3178 - Medicare Part B Improvement Act of 2017
- Implementation of the Affordable Care Act of 2010 (P.L. 111-148). - Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152). - Implementation of Orphan Drug Act of 1983 (P.L 97-414) and orphan drug development. - H.R. 6 - 21st Century Cures (P.L. 114-255).
Regulation of molecular diagnostics. House Committee on Energy & Commerce 21st Century Cures Initiative;Senate biomedical counterpart to H.R. 6.
-Federal funding and regulation of innovative gene therapy technologies. -H.R. 6: 21st Century Cures (P.L. 114-255).
Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics. S. 275 and H.R. 605 - Medicare Home Infusion Site of Care Act of 2015. H.R. 6 - 21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy.
Regulation of molecular diagnostics. House Committee on Energy & Commerce 21st Century Cures Initiative;Senate biomedical counterpart to H.R. 6.
Regulation of molecular diagnostics. H.R. 6 - 21st Century Cures Act (P.L. 114-255).
Regulation of molecular diagnostics. House Committee on Energy & Commerce 21st Century Cures Initiative;Senate biomedical counterpart to H.R. 6.
Medicare coverage of home infusion drugs and bioloigcals; payment for durable medical equipment drugs and biologicals. S. 275: Medicare Home Infusion Site of Care Act of 2015. H.R. 605: Medicare Home Infusion Site of Care Act of 2015.
Medicare coverage of home infusion drugs and bioloigcals; payment for durable medical equipment drugs and biologicals. S. 275: Medicare Home Infusion Site of Care Act of 2015. H.R. 605: Medicare Home Infusion Site of Care Act of 2015.
Medicare coverage of home infusion drugs and bioloigcals; payment for durable medical equipment drugs and biologicals. S. 275: Medicare Home Infusion Site of Care Act of 2015. H.R. 605: Medicare Home Infusion Site of Care Act of 2015.
Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics. S. 275 and H.R. 605 - Medicare Home Infusion Site of Care Act of 2015. H.R. 6 - 21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy.
Medicare coverage of home infusion drugs and bioloigcals; payment for durable medical equipment drugs and biologicals. S. 275: Medicare Home Infusion Site of Care Act of 2015. H.R. 605: Medicare Home Infusion Site of Care Act of 2015.
Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics. S. 275 and H.R. 605 - Medicare Home Infusion Site of Care Act of 2015. H.R. 6 - 21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy.
Medicare coverage of home infusion drugs and bioloigcals; payment for durable medical equipment drugs and biologicals. S. 275: Medicare Home Infusion Site of Care Act of 2015. H.R. 605: Medicare Home Infusion Site of Care Act of 2015.
Medicare coverage of home infusion drugs and bioloigcals; payment for durable medical equipment drugs and biologicals. S. 275: Medicare Home Infusion Site of Care Act of 2015. H.R. 605: Medicare Home Infusion Site of Care Act of 2015.
Protecting Access to Medicare Act of 2014
Client: COALITION FOR THE 21ST CENTURY · Firm: FOLEY HOAG LLP
Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.
Protecting Access to Medicare Act of 2014
Client: COALITION FOR THE 21ST CENTURY · Firm: FOLEY HOAG LLP
Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.
Protecting Access to Medicare Act of 2014
Client: COALITION FOR THE 21ST CENTURY · Firm: FOLEY HOAG LLP
Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.
Reauthorization of ESEA S. 1177 (Every Child Achieves Act of 2015). H.R. 5 (Student Success Act)
Reauthorization of ESEA S. 1177 (Every Child Achieves Act of 2015). H.R. 5 (Student Success Act)
Medicare coverage of home infusion drugs and bioloigcals; payment for durable medical equipment drugs and biologicals. S. 275: Medicare Home Infusion Site of Care Act of 2015. H.R. 605: Medicare Home Infusion Site of Care Act of 2015.
Reauthorization of ESEA S. 1177 (Every Child Achieves Act of 2015). H.R. 5 (Student Success Act)
Reauthorization of ESEA S. 1177 (Every Child Achieves Act of 2015).
Reauthorization of ESEA S. 1177 (Every Child Achieves Act of 2015). H.R. 5 (Student Success Act)
Medicare coverage of home infusion drugs and bioloigcals; payment for durable medical equipment drugs and biologicals. S. 275: Medicare Home Infusion Site of Care Act of 2015. H.R. 605: Medicare Home Infusion Site of Care Act of 2015.
Protecting Access to Medicare Act of 2014
Client: COALITION FOR THE 21ST CENTURY · Firm: FOLEY HOAG LLP
Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.
Protecting Access to Medicare Act of 2014
Client: COALITION FOR THE 21ST CENTURY · Firm: FOLEY HOAG LLP
Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.
Protecting Access to Medicare Act of 2014
Client: COALITION FOR THE 21ST CENTURY · Firm: FOLEY HOAG LLP
Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: FOLEY HOAG LLP
Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.
Protecting Access to Medicare Act of 2014
Client: COALITION FOR THE 21ST CENTURY · Firm: FOLEY HOAG LLP
Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.
Protecting Access to Medicare Act of 2014
Client: COALITION FOR THE 21ST CENTURY · Firm: FOLEY HOAG LLP
Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.
Protecting Access to Medicare Act of 2014
Client: MYRIAD GENETIC LABORATORIES, INC. · Firm: FOLEY HOAG LLP
Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.
Protecting Access to Medicare Act of 2014
Client: COALITION FOR THE 21ST CENTURY · Firm: FOLEY HOAG LLP
Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.
Protecting Access to Medicare Act of 2014
Client: COALITION FOR THE 21ST CENTURY · Firm: FOLEY HOAG LLP
Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.
Protecting Access to Medicare Act of 2014
Client: MCKESSON CORPORATION · Firm: FOLEY HOAG LLP
Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.
Protecting Access to Medicare Act of 2014
Client: MCKESSON CORPORATION · Firm: FOLEY HOAG LLP
Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.
Protecting Access to Medicare Act of 2014
Client: COALITION FOR THE 21ST CENTURY · Firm: FOLEY HOAG LLP
Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.
Medicare payment and coding for durable medical equipment; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.
Medicare payment and coding for durable medical equipment; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.
American Taxpayer Relief Act of 2012
Client: COALITION FOR THE 21ST CENTURY · Firm: FOLEY HOAG LLP
Implementation of the American Taxpayer Relief Act of 2012 Pub.L. 112240, H.R. 8
American Taxpayer Relief Act of 2012
Client: COALITION FOR THE 21ST CENTURY · Firm: FOLEY HOAG LLP
Implementation of the American Taxpayer Relief Act of 2012 Pub.L. 112240, H.R. 8 Regulation of laboratory-developed tests.
American Taxpayer Relief Act of 2012
Client: COALITION FOR THE 21ST CENTURY · Firm: FOLEY HOAG LLP
Implementation of the American Taxpayer Relief Act of 2012 Pub.L. 112240, H.R. 8
American Taxpayer Relief Act of 2012
Client: COALITION FOR THE 21ST CENTURY · Firm: FOLEY HOAG LLP
Implementation of the American Taxpayer Relief Act of 2012 Pub.L. 112240, H.R. 8 Regulation of laboratory-developed tests.
American Taxpayer Relief Act of 2012
Client: COALITION FOR THE 21ST CENTURY · Firm: FOLEY HOAG LLP
Implementation of the American Taxpayer Relief Act of 2012 Pub.L. 112240, H.R. 8
American Taxpayer Relief Act of 2012
Client: COALITION FOR THE 21ST CENTURY · Firm: FOLEY HOAG LLP
Implementation of the American Taxpayer Relief Act of 2012 Pub.L. 112240, H.R. 8
Regenerative Medicine Promotion Act of 2011
Client: ORGANOGENESIS INC. · Firm: FOLEY HOAG LLP
Medicare payment for biologics; Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148) (Delivery reforms) H.R. 1862 Regenerative Medicine Promotion Act of 2011; Budget Control Act of 2011(P.L. 112-25) (Part B payment for drugs and biologics)
Regenerative Medicine Promotion Act of 2011
Client: ORGANOGENESIS INC. · Firm: FOLEY HOAG LLP
Medicare payment for biologics; Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148) (Delivery reforms) H.R. 1862 Regenerative Medicine Promotion Act of 2011; Budget Control Act of 2011(P.L. 112-25) (Part B payment for drugs and biologics)
Regenerative Medicine Promotion Act of 2011
Client: ORGANOGENESIS INC. · Firm: FOLEY HOAG LLP
Medicare payment for biologics; Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148) (Delivery reforms) H.R. 1862 Regenerative Medicine Promotion Act of 2011; Budget Control Act of 2011(P.L. 112-25) (Part B payment for drugs and biologics)
Regenerative Medicine Promotion Act of 2011
Client: ORGANOGENESIS INC. · Firm: FOLEY HOAG LLP
Medicare payment for biologics; Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148) (Delivery reforms) H.R. 1862 Regenerative Medicine Promotion Act of 2011; Budget Control Act of 2011(P.L. 112-25) (Part B payment for drugs and biologics)
Regenerative Medicine Promotion Act of 2011
Client: ORGANOGENESIS INC. · Firm: FOLEY HOAG LLP
Medicare payment for biologics; Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148) (Delivery reforms) H.R. 1862 Regenerative Medicine Promotion Act of 2011; Budget Control Act of 2011(P.L. 112-25) (Part B payment)
Regenerative Medicine Promotion Act of 2011
Client: ORGANOGENESIS INC. · Firm: FOLEY HOAG LLP
Medicare payment for biologics; Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148) (Delivery reforms) H.R. 1862 Regenerative Medicine Promotion Act of 2011; Budget Control Act of 2011(P.L. 112-25) (Part B payment for drugs and biologics)
Preserving Access to Life-Saving Medications Act of 2011
Client: SPECTRUM PHARMACEUTICALS · Firm: FOLEY HOAG LLP
FDA authority for notification of drug shortages; S. 296 and H.R. 2245 Preserving Access to Life-Saving Medications Act
Preserving Access to Life-Saving Medications Act of 2011
Client: SPECTRUM PHARMACEUTICALS · Firm: FOLEY HOAG LLP
FDA authority for notification of drug shortages; S. 296 and H.R. 2245 Preserving Access to Life-Saving Medications Act
Patient Protection and Affordable Care Act- HR 3590 Medicare Coveratge and Reimbursement Issue
Patient Protection and Affordable Care Act (H.R. 3590); Health Care and Education Affordability Reconciliation Act (H.R. 4872)
American Middle Class Tax (AMT) Relief Act of 2007
Client: SANOFI US SERVICES INC · Firm: FOLEY HOAG LLP
Patient Protection and Affordable Care Act (H.R. 3590); Health Care and Education Affordability Reconciliation Act (H.R. 4872)
American Middle Class Tax (AMT) Relief Act of 2007
Client: NATIONAL VENTURE CAPITAL ASSOCIATION · Firm: FOLEY HOAG LLP
Patient Protection and Affordable Care Act (H.R. 3590); Health Care and Education Affordability Reconciliation Act (H.R. 4872)
To suspend temporarily the duty on 1-Amino-2,6-dimethylbenzene.
Client: AMGEN · Firm: FOLEY HOAG LLP
Patient Protection and Affordable Care Act (H.R. 3590); Health Care and Education Affordability Reconciliation Act (H.R. 4872)
2024 · second_quarter · Q2
-Regulation of molecular diagnostics -Issues relating to Cures 2.0 Bill
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2024 · first_quarter · Q1
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
-Regulation of molecular diagnostics -Issues relating to Cures 2.0 Bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2023 · fourth_quarter · Q4
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
-Regulation of molecular diagnostics -Issues relating to Cures 2.0 Bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2023 · third_quarter · 3A
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
-Regulation of molecular diagnostics -Issues relating to Cures 2.0 Bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2023 · third_quarter · Q3
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
-Regulation of molecular diagnostics -Issues relating to Cures 2.0 Bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2023 · second_quarter · Q2
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
-Regulation of molecular diagnostics -Issues relating to Cures 2.0 Bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2023 · first_quarter · Q1
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
-Regulation of molecular diagnostics -Issues relating to Cures 2.0 Bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2022 · fourth_quarter · Q4
-Regulation of molecular diagnostics -Issues relating to Cures 2.0 bill
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2022 · third_quarter · Q3
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
-Regulation of molecular diagnostics -Issues relating to Cures 2.0 bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2022 · second_quarter · Q2
-Regulation of molecular diagnostics -Issues relating to Cures 2.0 bill
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2022 · first_quarter · Q1
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
-Regulation of molecular diagnostics -Issues relating to Cures 2.0 bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2021 · fourth_quarter · Q4
-Regulation of molecular diagnostics -Issues relating to Cures 2.0 bill
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2021 · third_quarter · Q3
-Regulation of molecular diagnostics -Issues relating to Cures 2.0 bill
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2021 · second_quarter · Q2
-Regulation of molecular diagnostics -Issues relating to Cures 2.0 bill
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2021 · first_quarter · Q1
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2020 · fourth_quarter · Q4
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255) -Regulation of medical surprise billing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2020 · third_quarter · 3A
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255) -Regulation of medical surprise billing
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2020 · third_quarter · Q3
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255) -Regulation of medical surprise billing
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2020 · second_quarter · Q2
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255) -Regulation of medical surprise billing
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2020 · first_quarter · Q1
-Federal funding and regulation of innovative recombinant genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2020 · first_quarter · Q1
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255) -Regulation of medical surprise billing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2020 · first_quarter · Q1
-Medicare Part B and D payment for drugs -Issues related to the repeal of the non-interference clause in Part D
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of 21st Century Cures (P.L. 114-255) -Issues related to pandemic and seasonal influenza vaccine development -Issues related to the Pandemic and All Hazards Preparedness Innovation Act of 2019 -Issues related to over-the-counter drug and cosmetic reform legislation -Issues related to drug and insulin pricing
-Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
MYRIAD GENETICS, INC. via FOLEY HOAG LLP
2019 · fourth_quarter · 4T
-Medicare coverage and payment for clinical laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via FOLEY HOAG LLP
2019 · fourth_quarter · Q4
-Medicare coverage and payment for clinical laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2019 · fourth_quarter · Q4
-Federal funding and regulation of innovative recombinant genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2019 · fourth_quarter · Q4
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255) -Regulation of medical surprise billing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2019 · fourth_quarter · Q4
-Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Medicare Part B and D payment for drugs -Issues related to the repeal of the non-interference clause in Part D
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of 21st Century Cures (P.L. 114-255) -Issues related to pandemic and seasonal influenza vaccine development -Issues related to the Pandemic and All Hazards Preparedness Innovation Act of 2019 -Issues related to over-the-counter drug and cosmetic reform legislation -Issues related to drug and insulin pricing
MYRIAD GENETICS, INC. via FOLEY HOAG LLP
2019 · third_quarter · Q3
-Medicare coverage and payment for clinical laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2019 · third_quarter · Q3
-Federal funding and regulation of innovative recombinant genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2019 · third_quarter · Q3
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255)
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2019 · third_quarter · Q3
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of 21st Century Cures (P.L. 114-255) -Issues related to pandemic and seasonal influenza vaccine development -Issues related to the Pandemic and All Hazards Preparedness Innovation Act of 2019 -Issues related to over-the-counter drug and cosmetic reform legislation -Issues related to drug and insulin pricing
-Medicare Part B and D payment for drugs -Issues related to the repeal of the non-interference clause in Part D
-Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
SANOFI US SERVICES INC via FOLEY HOAG LLP
2019 · second_quarter · Q2
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of 21st Century Cures (P.L. 114-255) -Issues related to pandemic and seasonal influenza vaccine development -Reauthorization of Pandemic and All Hazards Preparedness (P.L. 109-417) -Issues related to over-the-counter drug and cosmetic reform legislation -Issues related to drug and insulin pricing
-Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Medicare Part B and D payment for drugs -Issues related to the repeal of the non-interference clause in Part D
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2019 · second_quarter · Q2
-Federal funding and regulation of innovative recombinant genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via FOLEY HOAG LLP
2019 · second_quarter · Q2
-Medicare coverage and payment for clinical laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2019 · second_quarter · Q2
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255)
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via FOLEY HOAG LLP
2019 · first_quarter · Q1
-Medicare coverage and payment for clinical laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2019 · first_quarter · Q1
-Federal funding and regulation of innovative recombinant genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2019 · first_quarter · Q1
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2019 · first_quarter · Q1
-Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of 21st Century Cures (P.L. 114-255) -Issues related to pandemic and seasonal influenza vaccine development -Reauthorization of Pandemic and All Hazards Preparedness (P.L. 109-417) -Issues related to over-the-counter drug and cosmetic reform legislation -Issues related to Right to Try -Issues related to drug and insulin pricing
-Medicare Part B and D payment for drugs -Issues related to the repeal of the non-interference clause in Part D
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2018 · fourth_quarter · Q4
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2018 · fourth_quarter · Q4
-Federal funding and regulation of innovative recombinant genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE via FOLEY HOAG LLP
2018 · fourth_quarter · Q4
-Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics -Implementation of 21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy -Implementation of Part B Home Infusion Services Temporary Transitional Payment Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2018 · fourth_quarter · Q4
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Medicare Part B and D payment for drugs -Issues related to the repeal of the non-interference clause in Part D
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
MYRIAD GENETICS, INC. via FOLEY HOAG LLP
2018 · fourth_quarter · Q4
-Medicare coverage and payment for clinical laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via FOLEY HOAG LLP
2018 · third_quarter · Q3
-Medicare coverage and payment for clinical laboratory test.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via FOLEY HOAG LLP
2018 · third_quarter · Q3
-Medicare payment and coverage for clinical laboratory tests
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2018 · third_quarter · Q3
-Federal funding and regulation of innovative recombinant genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE via FOLEY HOAG LLP
2018 · third_quarter · Q3
-Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics -Implementation of 21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy -Implementation of Part B Home Infusion Services Temporary Transitional Payment Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2018 · third_quarter · Q3
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255)
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2018 · third_quarter · Q3
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Medicare Part B and D payment for drugs -Issues related to the repeal of the non-interference clause in Part D
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of 21st Century Cures (P.L. 114-255) -Issues related to pandemic and seasonal influenza vaccine development -Reauthorization of Pandemic and All Hazards Preparedness (P.L. 109-417) -Issues related to over-the-counter drug and cosmetic reform legislation -Issues related to Right to Try -Issues related to drug and insulin pricing
BAXTER via FOLEY HOAG LLP
2018 · third_quarter · Q3
-General end-stage renal disease payment and reimbursement -Implementation of 21st Century Cures Legislation: Sec. 4013 - Telehealth Services in Medicare -Implementation of 21st Century Cures Legislation: Sec. 17006 - Allowing ESRD Beneficiaries to Choose A Medicare Advantage Plan -Implementation of Sec. 50302 of the Bipartisan Budget Act of 2018: Expanding Access To Home Dialysis Therapy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via FOLEY HOAG LLP
2018 · third_quarter · RR
-Medicare payment and coverage for clinical laboratory tests.
MYRIAD GENETIC LABORATORIES, INC. via FOLEY HOAG LLP
2018 · third_quarter · 3T
-Medicare payment and coverage for clinical laboratory tests
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2018 · second_quarter · Q2
-Federal funding and regulation of innovative recombinant genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via FOLEY HOAG LLP
2018 · second_quarter · Q2
-Medicare payment and coverage for clinical laboratory tests
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2018 · second_quarter · 2A
-Medicare Part B and D payment for drugs -Issues related to the repeal of the non-interference clause in Part D
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of 21st Century Cures (P.L. 114-255) -Issues related to pandemic and seasonal influenza vaccine development -Reauthorization of Pandemic and All Hazards Preparedness (P.L. 109-417) -Issues related to over-the-counter drug and cosmetic reform legislation -Issues related to Right to Try -Issues related to drug and insulin pricing
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2018 · second_quarter · Q2
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER via FOLEY HOAG LLP
2018 · second_quarter · Q2
-End-stage renal disease payment for home dialysis -Implementation of 21st Century Cures Legislation: Sec. 4013 - Telehealth Services in Medicare -Implementation of 21st Century Cures Legislation: Sec. 17006 - Allowing ESRD Beneficiaries to Choose A Medicare Advantage Plan -Implementation of Sec. 50302 of the Bipartisan Budget Act of 2018: Expanding Access To Home Dialysis Therapy -Payment for new technologies in the End-Stage Renal Disease Prospective Payment System
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2018 · second_quarter · Q2
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148) -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152) -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of 21st Century Cures (P.L. 114-255) -Issues related to pandemic and seasonal influenza vaccine development -Reauthorization of Pandemic and All Hazards Preparedness (P.L. 109-417) -Issues related to over-the-counter drug and cosmetic reform legislation -Issues related to Right to Try -Issues related to drug and insulin pricing
SHIRE via FOLEY HOAG LLP
2018 · second_quarter · Q2
-Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics -Implementation of 21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy -Implementation of Part B Home Infusion Services Temporary Transitional Payment Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2018 · first_quarter · Q1
-Medicare Part B and D payment for drugs -Issues relating to IPAB in S. 251 "Protecting Medicare from Executive Action of 2017" -Issues related to the repeal of the non-interference clause in Part D
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148) -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152) -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of 21st Century Cures (P.L. 114-255) -Issues related to pandemic and seasonal influenza vaccine development -Reauthorization of Pandemic and All Hazards Preparedness (P.L. 109-417) -Issues related to over-the-counter drug and cosmetic reform legislation -Issues related to Right to Try -Issues related to drug and insulin pricing
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2018 · first_quarter · Q1
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255)
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via FOLEY HOAG LLP
2018 · first_quarter · Q1
-Medicare payment and coverage for clinical laboratory tests
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2018 · first_quarter · Q1
-Federal funding and regulation of innovative recombinant genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE via FOLEY HOAG LLP
2018 · first_quarter · Q1
-Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics -Implementation of 21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy -Implementation of Part B Home Infusion Services Temporary Transitional Payment Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER via FOLEY HOAG LLP
2018 · first_quarter · Q1
-End-stage renal disease payment for home dialysis -Implementation of 21st Century Cures Legislation: Sec. 4013 - Telehealth Services in Medicare -Implementation of 21st Century Cures Legislation: Sec. 17006 - Allowing ESRD Beneficiaries to Choose A Medicare Advantage Plan -Implementation of Sec. 50302 of the Bipartisan Budget Act of 2018: Expanding Access To Home Dialysis Therapy -Payment for new technologies in the End-Stage Renal Disease Prospective Payment System
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE via FOLEY HOAG LLP
2017 · fourth_quarter · 4A
-Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics. -21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy. -H.R. 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act -H.R. 3178 - Medicare Part B Improvement Act of 2017
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER via FOLEY HOAG LLP
2017 · fourth_quarter · Q4
-End-stage renal disease payment for home dialysis. -Implementation of 21st Century Cures Legislation: Sec. 4013 - Telehealth Services in Medicare. -Implementation of 21st Century Cures Legislation: Sec. 17006 - Allowing ESRD Beneficiaries to Choose A Medicare Advantage Plan. -S. 870: Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE via FOLEY HOAG LLP
2017 · fourth_quarter · Q4
-Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics. -21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy. -H.R. 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act -H.R. 3178 - Medicare Part B Improvement Act of 2017
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2017 · fourth_quarter · Q4
-Medicare Part B payment for drugs.
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148). -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152). -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development. -Implementation of 21st Century Cures (P.L. 114-255). -Issues related to pandemic and seasonal influenza vaccine development. -Issues related to over-the-counter drug and cosmetic reform legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2017 · fourth_quarter · Q4
-Federal funding and regulation of innovative recombinant genetic technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2017 · fourth_quarter · Q4
-Regulation of molecular diagnostics. -Implementation of 21st Century Cures (P.L. 114-255).
-Medicare payment and coding for clinical laboratory tests. -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via FOLEY HOAG LLP
2017 · fourth_quarter · Q4
-Medicare payment and coverage for clinical laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2017 · third_quarter · Q3
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148). -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152). -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development. -Implementation of H.R. 6 - 21st Century Cures (P.L. 114-255). -S.2013 Trickett Wendler Right to Try Act of 2017. -H.R. 2430 and S. 932, FDA Reauthorization Act. -Issues related to Zika vaccine development. -Issues related to over-the-counter drug and cosmetic reform legislation.
-Medicare Part B payment for drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2017 · third_quarter · Q3
-Federal funding and regulation of innovative recombinant genetic technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via FOLEY HOAG LLP
2017 · third_quarter · Q3
-Medicare payment and coverage for clinical laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2017 · third_quarter · Q3
-Regulation of molecular diagnostics. -H.R. 6 - 21st Century Cures (P.L. 114-255).
-Medicare payment and coding for clinical laboratory tests. -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE via FOLEY HOAG LLP
2017 · third_quarter · Q3
-Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics. -H.R. 6 - 21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy. -H.R. 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act -H.R. 3178 - Medicare Part B Improvement Act of 2017
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER via FOLEY HOAG LLP
2017 · third_quarter · Q3
-End stage renal disease payment for home dialysis. -340B Drug Pricing Program. -Implementation of 21st Century Cures Legislation: Sec. 4013 - Telehealth Services in Medicare. -Implementation of 21st Century Cures Legislation: Sec. 17006 - Allowing ESRD Beneficiaries to Choose A Medicare Advantage Plan. -S. 870: Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2017 · second_quarter · Q2
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148). -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152). -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development. -H.R. 6 - 21st Century Cures (P.L. 114-255).
-Medicare Part B payment for drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2017 · second_quarter · Q2
-Federal funding and regulation of innovative recombinant genetic technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2017 · second_quarter · Q2
-Medicare payment and coding for clinical laboratory tests. -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93).
-Regulation of molecular diagnostics. -H.R. 6 - 21st Century Cures (P.L. 114-255).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE via FOLEY HOAG LLP
2017 · second_quarter · Q2
-Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics. -H.R. 6 - 21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy. -H.R. 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act -H.R. 3178 - Medicare Part B Improvement Act of 2017
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER via FOLEY HOAG LLP
2017 · second_quarter · Q2
-End stage renal disease payment for home dialysis. -340B Drug Pricing Program. -Implementation of 21st Century Cures Legislation: Sec. 4013 - Telehealth Services in Medicare. -Implementation of 21st Century Cures Legislation: Sec. 17006 - Allowing ESRD Beneficiaries to Choose A Medicare Advantage Plan. -CONNECT for Health Act of 2017 - Discussion Draft. - H.R. 28: Biological Implant Tracking and Veteran Safety Act of 2017.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via FOLEY HOAG LLP
2017 · second_quarter · Q2
-Medicare payment and coverage for clinical laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER via FOLEY HOAG LLP
2017 · first_quarter · Q1
-End stage renal disease payment for home dialysis. -340B Drug Pricing Program. -21st Century Cures Legislation: Sec. 4013 - Telehealth Services in Medicare. -21st Century Cures Legislation: Sec. 17006 - Allowing ESRD Beneficiaries to Choose A Medicare Advantage Plan. -CONNECT for Health Act of 2017 - Discussion Draft - H.R. 28: Biological Implant Tracking and Veteran Safety Act of 2017
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2017 · first_quarter · Q1
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148). -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152). -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development. -H.R. 6 - 21st Century Cures (P.L. 114-255).
-Medicare Part B payment for drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2017 · first_quarter · Q1
-Federal funding and regulation of innovative recombinant genetic technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via FOLEY HOAG LLP
2017 · first_quarter · Q1
-Medicare payment and coverage for clinical laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE via FOLEY HOAG LLP
2017 · first_quarter · Q1
-Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics. -H.R. 6 - 21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2017 · first_quarter · Q1
-Regulation of molecular diagnostics. -H.R. 6 - 21st Century Cures (P.L. 114-255).
-Medicare payment and coding for clinical laboratory tests. -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2016 · fourth_quarter · Q4
- Implementation of the Affordable Care Act of 2010 (P.L. 111-148). - Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152). - Implementation of Orphan Drug Act of 1983 (P.L 97-414) and orphan drug development. - H.R. 6 - 21st Century Cures (P.L. 114-255).
- Medicare Part B payment for drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2016 · fourth_quarter · Q4
-Federal funding and regulation of innovative recombinant genetic technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUEBIRD BIO via FOLEY HOAG LLP
2016 · fourth_quarter · RR
-Federal funding and regulation of innovative gene therapy technologies. -H.R. 6: 21st Century Cures (P.L. 114-255).
SHIRE via FOLEY HOAG LLP
2016 · fourth_quarter · Q4
Medicare coverage of home infusion drugs and biologics, including payment for durable medical equipment drugs and biologics. S. 275 and H.R. 605 - Medicare Home Infusion Site of Care Act of 2015. H.R. 6 - 21st Century Cures (P.L. 114-255): Sec. 5012 - Medicare Coverage of Home Infusion Therapy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETIC LABORATORIES, INC. via FOLEY HOAG LLP
2016 · fourth_quarter · Q4
Medicare payment and coverage for clinical laboratory tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2016 · fourth_quarter · Q4
Medicare payment and coding for clinical laboratory tests. Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93).
Regulation of molecular diagnostics. H.R. 6 - 21st Century Cures Act (P.L. 114-255).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER via FOLEY HOAG LLP
2016 · fourth_quarter · Q4
End stage renal disease payment for home dialysis. 340B Drug Pricing Program. 21st Century Cures Legislation: Sec. 4013 - Telehealth Services in Medicare. 21st Century Cures Legislation: Sec. 17006 - Allowing End-stage Renal Disease Beneficiaries To Choose A Medicare Advantage Plan.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE via FOLEY HOAG LLP
2016 · third_quarter · Q3
Medicare coverage of home infusion drugs and bioloigcals; payment for durable medical equipment drugs and biologicals. S. 275: Medicare Home Infusion Site of Care Act of 2015. H.R. 605: Medicare Home Infusion Site of Care Act of 2015.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of 21st Century Cures (P.L. 114-255) -Issues related to pandemic and seasonal influenza vaccine development -Reauthorization of Pandemic and All Hazards Preparedness (P.L. 109-417) -Issues related to over-the-counter drug and cosmetic reform legislation -Issues related to Right to Try -Issues related to drug and insulin pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
-Medicare Part B and D payment for drugs -Issues relating to IPAB in S. 251 "Protecting Medicare from Executive Action of 2017" -Issues related to the repeal of the non-interference clause in Part D
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE